Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly.

2.50
Hdl Handle:
http://hdl.handle.net/10541/82035
Title:
Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly.
Authors:
Drake, William M; Parkinson, Craig; Besser, G M; Trainer, Peter J
Abstract:
The elucidation of the mechanisms by which growth hormone (GH) interacts with its receptor has facilitated the design of compounds that function as GH-receptor antagonists. One such compound, B2036, has been conjugated to polyethylene glycol to produce a drug, pegvisomant, that has a powerful ability to lower circulating concentrations of insulin-like growth factor I (IGF-I), the principal mediator of GH action, in patients with acromegaly and to improve the symptoms and signs associated with GH excess. This article describes the mechanism of action of GH-receptor antagonists, reviews the preclinical and clinical data on the use of pegvisomant and discusses some of the challenges that lie ahead in judging the efficacy of a treatment that, unlike established therapies for acromegaly, does not aim to modify the underlying cause of acromegaly, namely excess GH secretion, but aims to lower serum IGF-I levels to normal.
Affiliation:
Department Endocrinology, St Bartholomew's Hospital, London, UK EC1A 7BE.
Citation:
Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. 2001, 12 (9):408-13 Trends Endocrinol. Metab.
Journal:
Trends in Endocrinology and Metabolism
Issue Date:
Nov-2001
URI:
http://hdl.handle.net/10541/82035
PubMed ID:
11595543
Type:
Article
Language:
en
ISSN:
1043-2760
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorDrake, William M-
dc.contributor.authorParkinson, Craig-
dc.contributor.authorBesser, G M-
dc.contributor.authorTrainer, Peter J-
dc.date.accessioned2009-09-22T11:02:08Z-
dc.date.available2009-09-22T11:02:08Z-
dc.date.issued2001-11-
dc.identifier.citationClinical use of a growth hormone receptor antagonist in the treatment of acromegaly. 2001, 12 (9):408-13 Trends Endocrinol. Metab.en
dc.identifier.issn1043-2760-
dc.identifier.pmid11595543-
dc.identifier.urihttp://hdl.handle.net/10541/82035-
dc.description.abstractThe elucidation of the mechanisms by which growth hormone (GH) interacts with its receptor has facilitated the design of compounds that function as GH-receptor antagonists. One such compound, B2036, has been conjugated to polyethylene glycol to produce a drug, pegvisomant, that has a powerful ability to lower circulating concentrations of insulin-like growth factor I (IGF-I), the principal mediator of GH action, in patients with acromegaly and to improve the symptoms and signs associated with GH excess. This article describes the mechanism of action of GH-receptor antagonists, reviews the preclinical and clinical data on the use of pegvisomant and discusses some of the challenges that lie ahead in judging the efficacy of a treatment that, unlike established therapies for acromegaly, does not aim to modify the underlying cause of acromegaly, namely excess GH secretion, but aims to lower serum IGF-I levels to normal.en
dc.language.isoenen
dc.subject.meshAcromegaly-
dc.subject.meshAnimals-
dc.subject.meshBiological Markers-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshInsulin-Like Growth Factor I-
dc.subject.meshReceptors, Somatotropin-
dc.titleClinical use of a growth hormone receptor antagonist in the treatment of acromegaly.en
dc.typeArticleen
dc.contributor.departmentDepartment Endocrinology, St Bartholomew's Hospital, London, UK EC1A 7BE.en
dc.identifier.journalTrends in Endocrinology and Metabolismen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.